Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

New data have shown that first-line treatment with a combination of two immunotherapy drugs improves overall survival in a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.